1 class of new drugs, generic drugs to come 6.5 billion varieties were "clamped"

Medical Network May 21 hearing May 20, Chengdu Brilliant medicine to generic oseltamivir phosphate Category 3 oseltamivir submitted a listing application to obtain dry suspension CDE contractors accepted; May 18, announced on Treasure Island, The company spent 150 million yuan to introduce a class of drugs for injection HNC042 anti-influenza virusFIG: 2015--2019 oseltamivir phosphate years domestic sales (unit: million)to oseltamivir represented neuraminidase inhibitor It is still the mainstream anti-influenza therapy, intranet meter data show that in 2019 retail sales in urban publicChinese county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal and the Chinese citiesoseltamivir phosphate terminal sales reached 6.554 billion yuan, an increase of 119.58%currently oseltamivir phosphate sales in the domestic market mainly oseltamivir capsules and granules, which sells terminal public medical institutions in China, East Sunshine drug products for leadingOseltamivir phosphate dry suspension as a new dosage form, there are Nobuyasu Pharmaceutical, Chengdu Brilliant Pharmaceutical submit a listing application to the new classificationgenerics addition, in recent years there have been a class of influenza clinical trials of new drugsMay 18, Treasure Island announced that the company spent 150 million yuan to introduce anti-influenza class of drugs for injection HNC042, its standard medication is the first new anti-flu drug peramivirperamivir Sodium Chloride Injection Guangzhou Pharmaceutical Southern New exclusive varieties, 2019 in China terminal sales in public sector exceeded 500 billion yuan, up 157.57 percentnow been accomplished by injection HNC042 project Phase I clinical trials in the United States showed good safety and tolerability, PK linear, Ⅱ of clinical trials support the implementationOctober 2018, the product obtained in the domestic clinical document, is about to start clinical trials.